(Q35558473)

8 August 2017

1 reference

title

Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control (English)

1 reference

8 August 2017

Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control (English)

1 reference

https://api.crossref.org/works/10.1016/S0163-4453(03)00096-3

20 March 2024

author name string

Enno Stürenburg

1

1 reference

8 August 2017

Dietrich Mack

2

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14556752

20 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0163445303000963?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0163-4453(03)00096-3

https://api.elsevier.com/content/article/PII:S0163445303000963?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0163-4453(03)00096-3

20 March 2024

1 reference

8 August 2017

47

1 reference

8 August 2017

273-295

1 reference

8 August 2017

4

1 reference

A functional classification scheme for beta-lactamases and its correlation with molecular structure

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

beta-Lactamases in laboratory and clinical resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

More extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Antimicrobial resistance in intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Evolution of plasmid-coded resistance to broad-spectrum cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

A standard numbering scheme for the class A beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Klebsiella pneumoniae strains more resistant to ceftazidime than to other third-generation cephalosporins.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

A novel extended-spectrum TEM-type beta-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Evolution of TEM-related extended-spectrum beta-lactamases in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Emergence of a carbapenem-resistant Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

1 reference

7 January 2021

Comparison of the sequences of class A beta-lactamases and of the secondary structure elements of penicillin-recognizing proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

A novel complex mutant beta-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum beta-lactamase-producing Klebsiellae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing beta-lactamase (CTX-M-10) isolated in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

CTX-M-5, a novel cefotaxime-hydrolyzing beta-lactamase from an outbreak of Salmonella typhimurium in Latvia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Chromosome-encoded Ambler class A beta-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Beta-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Kinetic interactions of tazobactam with beta-lactamases from all major structural classes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

A new plasmidic cefotaximase in a clinical isolate of Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Cefotaxime-hydrolysing beta lactamases in Morganella morganii.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Investigation of extended-spectrum beta-lactamase in Klebsiellae pneumoniae and Escherichia coli from China

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Distribution of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum beta-lactamase isolated from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Molecular characterization of a novel plasmid-encoded cefotaximase (CTX-M-12) found in clinical Klebsiella pneumoniae isolates from Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Spread of a Salmonella typhimurium clone resistant to expanded-spectrum cephalosporins in three European countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing beta-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Ceftazidime-hydrolysing CTX-M-15 extended-spectrum beta-lactamase (ESBL) in Poland

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Two different extended-spectrum beta-lactamases (ESBLs) in one of the first ESBL-producing salmonella isolates in Poland.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Countrywide spread of CTX-M-3 extended-spectrum beta-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Concurrent outbreaks of extended-spectrum beta-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

CTX-m-3 beta-lactamase-producing Escherichia coli from Greece

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Novel complex sul1-type integron in Escherichia coli carrying bla(CTX-M-9).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Identification and broad dissemination of the CTX-M-14 beta-lactamase in different Escherichia coli strains in the northwest area of Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

CTX-M extended-spectrum beta-lactamase arrives in the UK

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

OXA-18, a class D clavulanic acid-inhibited extended-spectrum beta-lactamase from Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 beta-lactamase from Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Carbapenems as inhibitors of OXA-13, a novel, integron-encoded beta-lactamase in Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

OXA-16, a further extended-spectrum variant of OXA-10 beta-lactamase, from two Pseudomonas aeruginosa isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Novel OXA-10-derived extended-spectrum beta-lactamases selected in vivo or in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

OXA-35 is an OXA-10-related beta-lactamase from Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among Escherichia coli and Klebsiella species in Hong KongNote

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

MYSTIC program: summary of European data from 1997 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Occurrence of extended-spectrum betalactamases (ESBL) in Dutch hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Susceptibility of Enterobacteriaceae to beta-lactam agents and fluoroquinolones: a 3-year survey in France.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Cefpodoxime screening of Escherichia coli and Klebsiella spp. by Vitek for detection of organisms producing extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Comparison of screening methods for TEM- and SHV-derived extended-spectrum beta-lactamase detection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Detection of extended-spectrum beta-lactamases in members of the family enterobacteriaceae: comparison of the MAST DD test, the double disc and the Etest ESBL.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Detection of extended-spectrum beta-lactamases with Etest and double-disc potentiation methods

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Validation of the VITEK2 and the Advance Expert System with a collection of Enterobacteriaceae harboring extended spectrum or inhibitor resistant beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Bases of variation in resistance to beta-lactams in Klebsiella oxytoca isolates hyperproducing K1 beta-lactamase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Use of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

In vitro evaluation of broad-spectrum beta-lactams in the philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

In vitro evaluation of cefepime and other broad-spectrum beta-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Do we need fourth-generation cephalosporins?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Perspectives of beta-lactamases inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third generation cephalosporins.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Piperacillin with and without tazobactam against extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa in a rat thigh abscess model.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Plasmid-borne AmpC beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Plasmid-determined AmpC-type beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Unusual Salmonella enterica serotype Typhimurium isolate producing CMY-7, SHV-9 and OXA-30 beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Prevalence of SHV-12 among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and identification of a novel AmpC enzyme (CMY-8) in Southern Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Quinolone resistance from a transferable plasmid.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Cloning and sequencing of Enterobacter aerogenes OmpC-type osmoporin linked to carbapenem resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Acquired carbapenemases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Pseudomonas aeruginosa: resistance and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Diversification of Escherichia coli expressing an SHV-type extended-spectrum beta-lactamase (ESBL) during a hospital outbreak: emergence of an ESBL-hyperproducing strain resistant to expanded-spectrum cephalosporins.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Epidemiological study by pulsed-field gel electrophoresis of an outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a geriatric hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Molecular epidemiology of an SHV-5 extended-spectrum beta-lactamase in enterobacteriaceae isolated from infants in a neonatal intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Convergent evolution of TEM-26, a beta-lactamase with extended-spectrum activity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Transposition of the gene encoding a TEM-12 extended-spectrum beta-lactamase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Characterization of In53, a class 1 plasmid- and composite transposon-located integron of Escherichia coli which carries an unusual array of gene cassettes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum beta-lactamase encoded by an Escherichia coli integron gene

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Nosocomial outbreak of Klebsiella pneumoniae producing SHV-5 extended-spectrum beta-lactamase, originating from a contaminated ultrasonography coupling gel.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

A hospital outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae investigated by RAPD typing and analysis of the genetics and mechanisms of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Detection and typing of extended-spectrum beta-lactamases in clinical isolates of the family Enterobacteriaceae in a medical center in Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900096-3

7 January 2021

Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals

59

1 reference

https://api.crossref.org/works/10.1016/S0163-4453(03)00096-3

Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates

20 March 2024

81

1 reference

https://api.crossref.org/works/10.1016/S0163-4453(03)00096-3

Treatment options for extended-spectrum beta-lactamase-producers

20 March 2024

132

1 reference

https://api.crossref.org/works/10.1016/S0163-4453(03)00096-3

20 March 2024

Identifiers

1 reference

8 August 2017

1 reference